Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Lava Therapeutics N.V. (NQ: LVTX )

2.730 +0.090 (+3.41%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 49,932
Open 2.700
Bid (Size) 2.700 (1)
Ask (Size) 2.990 (2)
Prev. Close 2.640
Today's Range 2.680 - 2.820
52wk Range 1.131 - 6.470
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
LVTX Stock Earnings: LAVA Therapeutics Misses EPS, Misses Revenue for Q4 2023
LVTX stock results show that LAVA Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
From LAVA Therapeutics N.V.
Via GlobeNewswire

Performance

YTD
+55.74%
+55.74%
1 Month
-18.02%
-18.02%
3 Month
+50.00%
+50.00%
6 Month
+131.36%
+131.36%
1 Year
+80.79%
+80.79%

More News

Read More
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
From LAVA Therapeutics N.V.
Via GlobeNewswire
What 5 Analyst Ratings Have To Say About LAVA Therapeutics
Via Benzinga
Recap: LAVA Therapeutics Q1 Earnings
Via Benzinga
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
Via FinancialNewsMedia
Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI
Via AB Newswire
Topics Retirement
Exposures Pension
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet (Donald Trump Has Re-Entered The Chat)
Via Benzinga
Topics Government
Exposures Political
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
From FN Media Group LLC
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Crude Oil Rises 2%; Tesla Shares Plunge After Downbeat Results
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Dow Surges Over 100 Points; US GDP Growth Tops Estimates
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Cancer Focused LAVA Therapeutics Nano Cap Stock Trading Higher Today?
Via Benzinga
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
From LAVA Therapeutics N.V.
Via GlobeNewswire
Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
From LAVA Therapeutics N.V.
Via GlobeNewswire
Why Lululemon Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Guidewire Software Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development
From LAVA Therapeutics N.V.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.